Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
NCT05780905
Recruiting
A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The study will randomize subjects with diabetes to either semaglutide or matching placebo. Magnetic resonance images will be primary endpoint measured at baseline and at one year to assess effect of this FDA approved medication. Given th... Read More
Gender:
ALL
Ages:
Between 40 years and 65 years
Trial Updated:
06/04/2024
Locations: University of Washington - Harborview Medical Center, Seattle, Washington
Conditions: Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack
Register for Updates
Impact of Semaglutide on CD34+ EPC and Fat Derived MSC
NCT04126603
Completed
The Investigator is trying to ascertain whether an FDA approved medication of T2DM, Semaglutide, can improve the number, function and gene expression of subjects CD34+ endothelial progenitor cells. EPCs are the source of cells protecting the inner lining of blood vessels and improving their survivability will improve cardiovascular outcome as high glucose environment of diabetes are toxic to these EPC Cells. Improve mitochondrial metabolism of Mesenchymal Stem Cell from subcutaneous fatty tissu... Read More
Gender:
ALL
Ages:
Between 20 years and 90 years
Trial Updated:
04/24/2024
Locations: The GW Medical Faculty Associates, Washington, District of Columbia +1 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
NCT06083675
Withdrawn
This study compares the medicines semaglutide with empagliflozin or metformin in people with newly diagnosed type 2 diabetes. This study will look mainly at how well participant's blood sugar and body weight are controlled when they are taking the study medicines. Participants will either get semaglutide tablets, empagliflozin tablets or metformin tablets. Which treatment participants will get is decided by chance. Currently, doses of 3 milligram (mg), 7 mg and 14 mg semaglutide tablets (Rybelsu... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
02/23/2024
Locations: Hillcrest Family Health Center, Waco, Texas +100 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
NCT04741074
Terminated
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or dialysis-dependent end-stage kidney disease (ESKD) on patients' eligibility for kidney transplantation at the end of 9 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Geisinger Medical Center, Danville, Pennsylvania +1 locations
Conditions: CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
Register for Updates
Treatment of GLP-1 for Diabetic Bariatric Patients
NCT04624672
Terminated
This study is for patients that are diabetic, and require insulin for glycemic control, and going through the bariatric surgery process. This is a prospective study that is trying to determine if the introduction of a semaglutide increases the remission rates of diabetes post-operatively.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/31/2023
Locations: Geisinger Medical Center, Danville, Pennsylvania
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Semaglutide Treatment On Coronary Progression
NCT03985384
Completed
The purpose of this research study is to see the effect of the diabetes medicine Semaglutide on a condition called atherosclerosis. Atherosclerosis is a narrowing, blockage, or hardening of the arteries due to a build up of calcium. This study will look specifically at the arteries involving the heart.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
10/03/2023
Locations: Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, California
Conditions: Type 2 Diabetes, Coronary Artery Disease
Register for Updates
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
NCT06005012
Recruiting
Conduct a community intervention study that will 1) validate a screening approach to identify patients at risk for advanced NAFLD in the obese or T2DM population, and 2) test whether semaglutide treatment is effective for the management of significant fibrosis due to NAFLD in high-risk patients.
Gender:
ALL
Ages:
Between 40 years and 79 years
Trial Updated:
09/01/2023
Locations: University of California, San Diego, La Jolla, California
Conditions: Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
Register for Updates
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors
NCT05768945
Active Not Recruiting
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/17/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes
Register for Updates
Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care
NCT04938388
Terminated
Researchers at Sansum Diabetes Research Institute want to learn more about how taking a new approved drug called oral Semaglutide, while eating fresh vegetables, impacts health in Hispanic/Latino adults with type 2 diabetes. This study drug is approved by the United States Food and Drug Administration and may be available by prescription for type 2 diabetes. To do this, 100 Hispanic/Latino adults who have type 2 diabetes will be split into two groups. Over one year, one group will take Semagluti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2023
Locations: Sansum Diabetes Research Institute, Santa Barbara, California
Conditions: Diabetes Mellitus, Type 2, Glucose Metabolism Disorders (Including Diabetes Mellitus)
Register for Updates
Once Weekly GLP-1 in Persons With Spinal Cord Injury
NCT03292315
Completed
Chronic spinal cord injury (SCI) results in adverse soft tissue body composition changes and an extremely sedentary lifestyle. These abrupt changes often lead to a high prevalence of cardiometabolic diseases, such as impaired glucose tolerance/diabetes mellitus and dyslipidemia, conditions which predispose those with SCI to an increased risk for cardiovascular disease compared to the general population. Due to paralysis and wheel chair dependence, maintaining an adequate level of physical activi... Read More
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
03/10/2023
Locations: Kessler Institute for Rehabilitation, West Orange, New Jersey
Conditions: Spinal Cord Injuries, Insulin Resistance, Pre Diabetes, Obesity
Register for Updates
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
NCT03989232
Completed
This study compares the effect of two doses of semaglutide (1.0 mg and 2.0 mg) in people with type 2 diabetes (T2D). People taking part in the study will take the medicine together with their current diabetes medicine (sulphonylurea and/or metformin). Participants will get a dose of either 1.0 mg or 2.0 mg semaglutide once a week - which dose is decided by chance. Participants will inject semaglutide under the skin once a week. The study will last for about 49 weeks. Participants will have 9 cli... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2023
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +128 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
The SLIM LIVER Study
NCT05654051
Active, Not Recruiting
The purpose of this study is to evaluate the safety and tolerability of a drug called semaglutide and to see whether it can reduce IHTG. IHTG will be measured by magnetic resonance imaging (MRI; an MRI machine contains a powerful magnet that uses simple radio waves to take pictures of organs). Semaglutide (brand name Ozempic®) is a drug that is used to treat people who have diabetes; it also causes weight loss and may provide some protection against cardiovascular disease and diabetes. In PLWH,... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/07/2022
Locations: 31788 Alabama CRS, Birmingham, Alabama +7 locations
Conditions: HIV-1-infection, Adiposity, Insulin Resistance, Pre-diabetes, Hepatic Steatosis
Register for Updates